LVM Capital Management Ltd. MI Acquires New Stake in Moderna, Inc. $MRNA

LVM Capital Management Ltd. MI purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 14,290 shares of the company’s stock, valued at approximately $421,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRNA. MUFG Securities EMEA plc purchased a new position in Moderna in the second quarter worth $28,000. Ameriflex Group Inc. boosted its position in shares of Moderna by 3,775.0% during the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock worth $32,000 after purchasing an additional 1,208 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares during the period. CVA Family Office LLC increased its holdings in shares of Moderna by 1,229.7% in the 4th quarter. CVA Family Office LLC now owns 1,476 shares of the company’s stock valued at $44,000 after purchasing an additional 1,365 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Moderna in the 3rd quarter valued at about $43,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on MRNA. Morgan Stanley set a $30.00 price objective on shares of Moderna in a report on Monday, February 16th. UBS Group reaffirmed a “neutral” rating and issued a $36.00 price target on shares of Moderna in a report on Monday, February 16th. Sanford C. Bernstein reissued a “market perform” rating and set a $45.00 price objective on shares of Moderna in a research note on Tuesday, February 17th. The Goldman Sachs Group lifted their price objective on Moderna from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Finally, Royal Bank Of Canada upped their target price on Moderna from $25.00 to $30.00 and gave the company a “sector perform” rating in a research note on Tuesday, February 17th. Two equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $32.33.

Moderna Price Performance

NASDAQ:MRNA opened at $53.54 on Thursday. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $59.55. The firm has a market cap of $21.15 billion, a price-to-earnings ratio of -7.36 and a beta of 1.29. The company’s 50-day moving average is $48.22 and its two-hundred day moving average is $34.82. The company has a current ratio of 3.29, a quick ratio of 3.22 and a debt-to-equity ratio of 0.07.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, February 13th. The company reported ($2.11) EPS for the quarter, topping analysts’ consensus estimates of ($2.79) by $0.68. The business had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The company’s quarterly revenue was down 33.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.91) earnings per share. Research analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Insider Transactions at Moderna

In other Moderna news, President Stephen Hoge sold 160,009 shares of Moderna stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $48.84, for a total value of $7,814,839.56. Following the completion of the sale, the president directly owned 1,457,427 shares of the company’s stock, valued at approximately $71,180,734.68. The trade was a 9.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.80% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.